Effects of CAP-regimen Chemotherapy on Blood Redox Status in Patients with Ovarian Cancer

• Published in: Anti-cancer agents in medicinal chemistry Vol. 15; no. 9; p. 1141
• Main Authors: Antoneeva, Inna I, Dolgova, Dinara R, Gening, Tatyana P, Abakumova, Tatyana V, Gening, Snezhanna O, Pirmamedova, Sabina S, Fomina, Anastasia V, Mikheenko, Alla A
• Format: Journal Article
• Language: English
• Published: Netherlands 01-01-2015
• Subjects: Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Catalase - blood; Cisplatin - therapeutic use; Cyclophosphamide - therapeutic use; Doxorubicin - therapeutic use; Female; Glutathione Transferase - blood; Humans; Malondialdehyde - metabolism; Middle Aged; Ovarian Neoplasms - blood; Ovarian Neoplasms - drug therapy; Oxidation-Reduction; Superoxide Dismutase - blood
• ISSN: 1875-5992
• DOI: 10.2174/1871520615666150526102243

Ovarian cancer (OC) is the most lethal of gynecologic tumors because women generally present with advanced stage disease. Platinum-based chemotherapy play a pivotal role in OC treatment. The aim of the study was to assess the effects of CAP-regimen chemotherapy on blood redox status in patients with ovarian cancer.
Patients were 132 women with primary OC with FIGO stage III-IV. Patients were examined before treatment, 3 and 14 days after the first and 3 and 14 days after the second course of CAP-regimen chemotherapy. The activity of antioxidant enzymes, the intensity of lipid peroxidation, the level of oxidative modification of proteins (OMP) were evaluated.
We have found elevated levels of OMP products in plasma and erythrocytes of patients with ovarian cancer in comparison with donors. Our results suggest activation of lipid peroxidation in plasma and erythrocytes of ovarian cancer patients in comparison with healthy women. Sensitive and specific indicators of oxidative stress are levels of glutathione-S-transferase (sensitivity 80%, specificity 89%), diene conjugates (sensitivity 85,71%, specificity 72,73%) and OMP 430 nm (sensitivity 80%, specificity 90%) in blood plasma and the activity of catalase in erythrocytes (sensitivity 100%, specificity 89%).
CAP chemotherapy in patients with ovarian cancer with FIGO stage III-IV induces radical formation and changes the homeostasis of the patient. The lipid peroxidation and antioxidant system in plasma move to a higher level of functioning, and the erythrocytes develop oxidative stress.